Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...
Currently, IONS has a robust portfolio of treatments for rare and prevalent diseases. This includes Spinraza for spinal muscular atrophy, Qalsody for SOD1-ALS, and its recently FDA-approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback